LONDON (Reuters) -Eli Lilly Chief Executive Dave Ricks said Britain was “probably the worst country in Europe” for drug prices in an interview with the Financial Times, intensifying pressure on the government to improve market conditions for drugmakers. The remarks are part of a broader backlash from pharmaceutical giants, including Merck and AstraZeneca, who have paused or scaled back investments in Britain over the challenging environment. Ricks said Britain would miss out on new drugs if it did not raise prices and scrap a rebate scheme which requires companies to contribute a portion of their UK drug revenue to the state-run NHS.Read More
